Hacia la conciencia social del consumo energético en centros de datos

Ante el problema creciente del consumo en los centros de datos, unido a la adopción paulatina de las mejores prácticas actuales para mejorar la eficiencia energética, se hace imprescindible un cambio radical en el enfoque de la energía en dichos centros de datos para poder seguir reduciendo de manera significativa su impacto medioambiental. En este artículo presentamos una propuesta inicial para la optimización integral del consumo de energía en centros de datos, que ha sido validado en un escenario de monitorización poblacional de salud, con ahorros de hasta un 50% frente al estado del arte en eficiencia energética. Defendemos una conciencia global del Estado y el comportamiento térmico del centro de datos, utilizando modelos predictivos para anticipar las variables determinantes para la optimización. Además, las estrategias de optimización energética de los centros de datos del futuro tienen que ser sociales: los distintos elementos (servidores, software de gestión, sistemas de refrigeración) deben tener cierta conciencia del estado de los demás elementos del sistema y de cómo el entorno los puede perjudicar o favorecer, buscando el consenso en estrategias colaborativas para reducir el consumo total

On the leakage-power modeling for optimal server operation

Leakage power consumption is a com- ponent of the total power consumption in data cen- ters that is not traditionally considered in the set- point temperature of the room. However, the effect of this power component, increased with temperature, can determine the savings associated with the careful management of the cooling system, as well as the re- liability of the system. The work presented in this paper detects the need of addressing leakage power in order to achieve substantial savings in the energy consumption of servers. In particular, our work shows that, by a careful detection and management of two working regions (low and high impact of thermal- dependent leakage), energy consumption of the data- center can be optimized by a reduction of the cooling budget

A novel energy-driven computing paradigm for e-health scenarios

A first-rate e-Health system saves lives, provides better patient care, allows complex but useful epidemiologic analysis and saves money. However, there may also be concerns about the costs and complexities associated with e-health implementation, and the need to solve issues about the energy footprint of the high-demanding computing facilities. This paper proposes a novel and evolved computing paradigm that: (i) provides the required computing and sensing resources; (ii) allows the population-wide diffusion; (iii) exploits the storage, communication and computing services provided by the Cloud; (iv) tackles the energy-optimization issue as a first-class requirement, taking it into account during the whole development cycle. The novel computing concept and the multi-layer top-down energy-optimization methodology obtain promising results in a realistic scenario for cardiovascular tracking and analysis, making the Home Assisted Living a reality

A cyber-physical approach to combined HW-SW monitoring for improving energy efficiency in data centers

High-Performance Computing, Cloud computing and next-generation applications such e-Health or Smart Cities have dramatically increased the computational demand of Data Centers. The huge energy consumption, increasing levels of CO2 and the economic costs of these facilities represent a challenge for industry and researchers alike. Recent research trends propose the usage of holistic optimization techniques to jointly minimize Data Center computational and cooling costs from a multilevel perspective. This paper presents an analysis on the parameters needed to integrate the Data Center in a holistic optimization framework and leverages the usage of Cyber-Physical systems to gather workload, server and environmental data via software techniques and by deploying a non-intrusive Wireless Sensor Net- work (WSN). This solution tackles data sampling, retrieval and storage from a reconfigurable perspective, reducing the amount of data generated for optimization by a 68% without information loss, doubling the lifetime of the WSN nodes and allowing runtime energy minimization techniques in a real scenario

Self-Organizing maps for detecting abnormal thermal behavior in data centers

The increasing success of Cloud Computing applications and online services has contributed to the unsustainability of data center facilities in terms of energy consumption. Higher resource demand has increased the electricity required by computation and cooling resources, leading to power shortages and outages, specially in urban infrastructures. Current energy reduction strategies for Cloud facilities usually disregard the data center topology, the contribution of cooling consumption and the scalability of optimization strategies. Our work tackles the energy challenge by proposing a temperature-aware {VM} allocation policy based on a {Trust-and-Reputation} System ({TRS}). A {TRS} meets the requirements for inherently distributed environments such as data centers, and allows the implementation of autonomous and scalable {VM} allocation techniques. For this purpose, we model the relationships between the different computational entities, synthesizing this information in one single metric. This metric, called reputation, would be used to optimize the allocation of {VMs} in order to reduce energy consumption. We validate our approach with a state-of-the-art Cloud simulator using real Cloud traces. Our results show considerable reduction in energy consumption, reaching up to 46.16\% savings in computing power and 17.38\% savings in cooling, without {QoS} degradation while keeping servers below thermal redlining. Moreover, our results show the limitations of the {PUE} ratio as a metric for energy efficiency. To the best of our knowledge, this paper is the first approach in combining {Trust-and-Reputation} systems with Cloud Computing {VM} allocation

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Effectiveness; Caplacizumab; Immune thrombotic thrombocytopenic purpuraEficàcia; Caplacizumab; Púrpura trombocitopènica trombòtica immunitàriaEficacia; Caplacizumab; Púrpura trombocitopénica trombótica inmunitariaImmune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX

Propuesta de virtualización de la docencia en la asignatura “Epigrafía y Numismática” (Grado en Historia, Grado en Arqueología y Máster en Arqueología).

Los objetivos principales son: 1.- Incentivar la educación virtual de la Epigrafía y de la Numismática permitiendo al alumnado conocer con detalle los actuales métodos de análisis y de trasferencia del conocimiento y generando una red de docencia que sea efectiva tanto en los periodos de docencia presencial, como en los momentos en los que las clases deban de impartirse a través de plataformas online. 2.- Impulsar sistemas de enseñanza de la Epigrafía (presencial/online) que permitan al alumnado comprender la importancia ideológica de los documentos escritos de exposición pública a lo largo de la Historia. 3.- Impulsar sistemas de enseñanza de la Numismática (presencial/online) que permitan al alumnado comprender que, independientemente de la época, la moneda ha sido, prácticamente desde su aparición, un instrumento de uso corriente que facilitaba el normal desarrollo de las distintas formas económicas de la sociedad (en especial, del desempeño de los pagos/cobros de bienes, servicios y salarios, del atesoramiento y expresión pública de la riqueza colectiva/privada, de la estimación del valor de cualquier bien, servicio y/o salario y de la ejecución de medidas oficiales de intervención en la economía de una determinada comunidad) y la integración efectiva de todos los miembros que las conformaban (sin restricciones ideológicas ni geográficas, pero tampoco de tipo práctico, dadas las características físicas del propio soporte monetario )

Anti-Inflammatory (M2) Response Is Induced by a sp(2)-Iminosugar Glycolipid Sulfoxide in Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the most common complications of Diabetes Mellitus (DM) and is directly associated with inflammatory processes. Currently, neuro-inflammation is considered an early event in DR and proceeds via microglia polarization. A hallmark of DR is the presence of retinal reactive gliosis. Here we report the beneficial effect of (S (S),1R)-1-docecylsulfiny-5N,6O-oxomethylidenenojirimycin ((Ss)-DS-ONJ), a member of the sp(2)-iminosugar glycolipid (sp(2)-IGL) family, by decreasing iNOS and inflammasome activation in Bv.2 microglial cells exposed to pro-inflammatory stimuli. Moreover, pretreatment with (Ss)-DS-ONJ increased Heme-oxygenase (HO)-1 as well as interleukin 10 (IL10) expression in LPS-stimulated microglial cells, thereby promoting M2 (anti-inflammatory) response by the induction of Arginase-1. The results strongly suggest that this is the likely molecular mechanism involved in the anti-inflammatory effects of (S (S))-DS-ONJ in microglia. (S (S))-DS-ONJ further reduced gliosis in retinal explants from type 1 diabetic BB rats, which is consistent with the enhanced M2 response. In conclusion, targeting microglia polarization dynamics in M2 status by compounds with anti-inflammatory activities offers promising therapeutic interventions at early stages of DR

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P <.05) and less refractoriness (4.5% vs 14.1%; P <.05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P <.05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P <.001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX